SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/217646"
 

Search: onr:"swepub:oai:gup.ub.gu.se/217646" > Impact of Host Gene...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Impact of Host Genetic Variants on Natural History and Treatment of Hepatitis C Virus Infection

Rembeck, Karolina (author)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
 (creator_code:org_t)
ISBN 9789162892814
2015
English.
  • Doctoral thesis (other academic/artistic)
Abstract Subject headings
Close  
  • Chronic hepatitis C Virus (HCV) infection causes liver disease and may progress to severe fibrosis, cirrhosis, and hepatocellular carcinoma. This thesis aimed to evaluate the impact of host genetics, i.e. genetic variants of PNPLA3, IL28B and ITPA, on liver disease severity and treatment outcome in HCV genotype 2 and 3 infected patients treated with pegylated interferon and ribavirin for either 12 or 24 weeks. In paper I, 359 patients were evaluated retrospectively with regards to the impact of the PNPLA3 genetic variants. No significant impact was observed on liver disease severity nor on treatment outcome, and the clinical need to screen Nordic HCV genotype 2 or 3 infected patients for these genetic variants seems low. In papers II and III, in post-hoc evaluation encompassing 339 Nordic HCV genotype 2 or 3 infected patients, genetic variants of the rs12979860 in proximity to IL28B were not associated with treatment outcome but the CCrs12979860 and the TTrs8099917 genetic variants (n=314) were found to be associated with more pronounced liver histopathology among HCV genotype 3 infected patients. Thus, these patients may benefit from early initiation of therapy. In paper IV, in a real life trial (n=737) enrolling HCV genotype 1-3 infected patients evaluated by means of transient elastography, CCrs12979860 was significantly associated with higher liver stiffness values among HCV genotype 3 infected patients; thus confirming the results of papers II and III in an independent cohort of patients. In paper V, in a post-hoc analysis of Nordic HCV genotype 2 or 3 infected patients treated with 800 mg ribavirin daily and interferon reduced ITPase (n=354) activity was significantly associated with increased likelihood of achieving sustained virological response. Thus the majority of patients having normal ITPase activity may benefit more from a higher weight-based dosing of ribavirin.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Keyword

hepatitis C
prognostic factors

Publication and Content Type

vet (subject category)
dok (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Rembeck, Karolin ...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Gastroenterology ...
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Infectious Medic ...
By the university
University of Gothenburg

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view